NCT02537613View on ClinicalTrials.gov

A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

March 31, 2020

Study Completion Date

January 31, 2027

Conditions
Chronic Lymphocytic Leukemia
Interventions
DRUG

Obinutuzumab

Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6

DRUG

Ibrutinib

Ibrutinib given once daily by mouth

Trial Locations (4)

14642

University of Rochester Wilmot Cancer Inst., Rochester

27710

Duke University Medical Center, Durham

02114

Massachusetts General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Dana-Farber Cancer Institute

OTHER